Moffitt Notice of Blackbaud Data Incident. Learn More
Neuroendocrine Tumor Survival Rate
The neuroendocrine tumor survival rate can vary significantly from patient to patient based on the location, type and stage of the cancer. Therefore, any general statistics relating to prognosis must be viewed within a proper context and are best understood with the help of a treating physician.
Is neuroendocrine cancer aggressive?
In many cases, neuroendocrine tumors are very small and slow growing. Studies show that these types of tumors can potentially last a lifetime without causing symptoms or spreading. As a result, the survival rate – especially for neuroendocrine tumors that are diagnosed in early stages and properly treated – can be favorable.
Things to consider about neuroendocrine tumor survival rates
While the overall neuroendocrine tumor survival rate can provide a helpful benchmark for physicians, it is of limited value to individual patients for several reasons. Consider that:
- The data is based on the collective experiences of thousands of people, and the actual outcome for a specific individual can be markedly different from the general average.
- It is impossible to predict the prognosis of any patient with a neuroendocrine tumor because every person responds differently to treatment.
- Survival statistics are captured in five-year intervals; therefore, they do not account for the most recent medical advances or breakthroughs in treatment approaches.
At Moffitt Cancer Center, each patient with a neuroendocrine tumor is evaluated thoroughly by a multispecialty team of experts who have the expertise necessary to design tailored treatment plans for every type of neuroendocrine cancer. Additionally, we have a surgical team that specializes exclusively in neuroendocrine tumor surgery and performs complex procedures with an unparalleled level of skill and precision.
Moffitt’s extensive research initiatives on neuroendocrine tumor treatment have received national recognition, and through our exciting clinical trial program, our patients have opportunities to be among the first to benefit from treatment advances, such as minimally invasive approaches and interventional radiology. As a National Cancer Institute designated Comprehensive Cancer Center, Moffitt provides each patient the best possible treatment options to improve his or her quality of life.
If you’d like to learn more about the neuroendocrine tumor survival rate, the experts at Moffitt can explain how it relates to your unique situation. Call 1-888-663-3488 or complete a new patient registration form online. No referrals are required.